| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2011: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Research Abstract |
From our screening program of microbial sources, we discovered albocycline and nosokophic acid as new small molecules that show specific activity against MRSA. Furthermore, we studied the mechanism of action of the compounds with unique chemical structure and biological activity.
As a result, we found that albocyclin is a new inhibitor of cell wall biosynthesis of MRSA. Furthermore, we took a proteomic strategy to identify the proteins that bind to cyslabdan. We successfully found that cyslabdan primarily targets FemA that is involved in the peptidoglycan synthesis of MRSA.
|
